In evaluating the effects of Selol administration on tumor size, mouse weight (as a measure of overall well-being), and PSA levels at the end of the experiment, significant variability was observed in the treated group (CV = 62% vs. 31% for tumor weight and 70% vs. 40% for PSA2 levels). This evidence concerns the gene KLK3 and neoplasm.